APOC3 and hypertriglyceridemia: In a phase 2b placebo controlled clinical trial involving 229 individuals with hypertriglyceridemia with TG level above 500 mg/dL it was demonstrated that subcutaneously injection of ARO-APOC3 (10, 25, 50 mg) led to reduction of Apoc3 level up to 77% and mean TG level to 57% decrease within 48 weeks.